PURPOSE: The combination of chemotherapy and radiotherapy is emerging as the new standard modality for the treatment of locally advanced @entity135 , due to the inherent functional and cosmetic sequelae associated with its surgical management. Combination chemotherapy with @entity1487 and @entity900 (FP) is one of the most active regimens for the @entity135 . Furthermore, both agents are known to act as radiosensitizer. This study was conducted to determine the efficacy, feasibility, and the @entity137 of concurrent FP chemotherapy with radiotherapy. MATERIALS AND METHODS: @entity1 with histologically proven locally advanced @entity135 (T3-4 or node positive) were enrolled in the study. @entity1 received @entity1487 , 1,000 mg/m2/day, continuously for 4 days, and @entity900 , 75 mg/m2, on day 1. This regimen was given every four weeks. The radiotherapy (45 Gy) was started on day 1 of the first cycle, and administered in 25 fractions. Following a three-week interval, the radiotherapy was resumed on day 1 of the third cycle of chemotherapy, and administered in 15 fractions (27 Gy). RESULTS: Of the 31 eligible @entity1 included, 28 were able to be evaluated for the @entity5 response. The response rate for the 28 @entity1 was 93% (16 complete responses, 10 partial responses). Disease free survival for the 16 complete responders was 37 months (median, 1 ~41 months), with a median follow-up time of 31 months. The 1-, 2-, and 3-year survival rates were 82%, 69%, and 63%, respectively. Regarding the feasibility of this treatments, only nineteen @entity1 (61%) received the complete courses of scheduled treatments. The median duration of admission for all @entity1 was 39 days. Grade 3 or 4 @entity3136 were observed in 25 @entity1 (83%) and appeared as the dose limiting @entity137 of this regimen. CONCLUSION: Although FP chemotherapy with concurrent radiotherapy is toxic, it is an effective and relatively feasible treatment for locally advanced @entity135 . The majority of @entity1 experienced severe @entity3136 , which appeared as the dose limiting @entity137 of this regimen.

XXXX and @entity900 (FP) with Concurrent Radiotherapy for Locally Advanced @entity135 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck cancer'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity3136 :: ('MESH:D013280', 'Disease') :: ['stomatitis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-fluorouracil']
@entity1487 :: (MESH:D005472,Chemical) :: ['5-Fluorouracil']
